Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17th: ProKidney Corp. PROK: This clinical-stage biotechnology company has a Zacks Rank #1 ...

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary ...

A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person in Europe to receive a ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second ...

Between 40 to 50 people in England are known to have APDS. The list price for leniolisib is £352,000 per person per year but the company Pharming has agreed a discount for the NHS. The team that ...

Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) ...

Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2025. To participate in the conference call, please register in advance using the link below. Once ...

On Thursday, H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating and a $37.00 price target for Pharming Group (NASDAQ: PHAR), representing significant upside potential from current ...